Fredrik Widman Sells 810 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Fredrik Widman sold 810 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total value of $464,761.80. Following the completion of the transaction, the vice president now owns 473 shares in the company, valued at approximately $271,397.94. The trade was a 63.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Intuitive Surgical Trading Down 1.6 %

Shares of Intuitive Surgical stock opened at $557.96 on Wednesday. The business’s fifty day simple moving average is $571.08 and its 200 day simple moving average is $530.63. The firm has a market capitalization of $198.73 billion, a P/E ratio of 87.05, a price-to-earnings-growth ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00.

Institutional Trading of Intuitive Surgical

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Intuitive Surgical by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider’s stock worth $16,813,478,000 after buying an additional 360,591 shares during the last quarter. State Street Corp increased its position in Intuitive Surgical by 1.4% in the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock worth $7,393,673,000 after buying an additional 210,363 shares during the last quarter. FMR LLC increased its position in Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after buying an additional 838,793 shares during the last quarter. Geode Capital Management LLC increased its position in Intuitive Surgical by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider’s stock worth $4,039,200,000 after buying an additional 243,802 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Intuitive Surgical by 1.8% in the fourth quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider’s stock worth $2,541,356,000 after buying an additional 86,488 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Leerink Partners increased their price target on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. BTIG Research increased their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Jefferies Financial Group raised their target price on Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Finally, Evercore ISI raised their target price on Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.